| Compound |
Target |
Indication (Combination) |
Stage of Development |
Partner |
| AEG35156 |
X-Linked Inhibitor of Apoptosis (XIAP) |
2nd Line AML (High Dose Arac/Idarubicin) |
Randomized Phase 2 |
|
 |
| |
|
HCC (Sorafenib) |
Randomized Phase 2 |
|
|
| |
|
CLL/B-Cell Lymphoma |
Phase I/2 |
 |
|
| AEG40826 (HGS1029) |
Inhibitor of Apoptosis Proteins (IAPs) |
Solid Tumors
Lymphoid Tumors |
Phase I
Phase I |
 |
|
| AEGXXXXX |
Inhibitor of Apoptosis Proteins (IAPs) |
Inflammatory/Autoimmune Diseases |
Preclinical Development Candidate Selection |
|
|
